OpenAI hits a $1.25 trillion valuation, but the cooling market cut short its $1.4 trillion ambitions

OpenAI is now valued at $1.25 trillion after a new funding round that raised $11 billion, according to Bloomberg, as reported by The Verge. That makes it one of the most valuable companies in the world. In March, it raised $122 billion at a valuation of $852 billion. The new figure is about 47% higher, eight months later.

The headline hides a retreat. Bloomberg says OpenAI initially hoped to raise as much as $30 billion at a $1.4 trillion valuation. The amount raised so far is barely a third of that target. The valuation is about 11% below the hoped-for figure. OpenAI is still seeking more money, which could bring the round to $20 billion, echoing earlier reports from the Financial Times and the Wall Street Journal. The Verge says the plans changed after tech stocks fell and the US midterm results showed how far public opinion has turned against AI companies and data center projects.

The timing matters. Rival Anthropic filed its S-1 to go public last week. OpenAI CEO Sam Altman said earlier this year that the company will delay its own IPO until it can make more confident claims about its models' safety. He gave no timeline, but added: "I think it's also kind of bad for the world if OpenAI waits too long to go public." The two leading frontier labs are taking different paths to capital. Anthropic is going to public investors and their scrutiny. OpenAI is staying private and raising from a smaller group of backers.

Our thesis: the AI boom has hit its first real resistance, and it comes from society as much as from markets. A selloff can recover in weeks. Public distrust of data centers is harder to reverse, and it affects what these valuations depend on most: permission to build compute at enormous scale.

Our reading: this is a correction, not a collapse, and it may be useful. The money still flows: $11 billion in one round is more than most companies raise in their lifetime. But voters are pushing back while the gains still go mostly to investors and insiders. That shows a gap we have flagged before: capitalization is not the same as abundance. The long-term case remains strong. AI that speeds up medicine and makes work more productive could justify trillion-dollar valuations. Getting there requires the sector to earn back public consent with visible, shared benefits, not just higher valuations. Altman's link between safety and going public points in the right direction, if it turns out to be a real commitment and not just a convenient delay.